Evidence continues to accumulate on the increased relative efficacy of some therapies for Clostridioides difficile infection (CDI), especially with respect to the prevention of recurrent infection. There are 4 currently approved therapeutic agents for managing CDI: 2 older antibiotics, metronidazole and vancomycin, and 2 newer options, the antibiotic fidaxomicin (Dificid, Merck) and, most recently, a monoclonal antibody against 1 of the 2 major C. difficile toxins
JANUARY 6, 2020